Scott H. Bice

Robert C. & Nanette T. Packard Professor of Law at University of Southern California Gould School of Law

Scott H. Bice

Scott H. Bice

Robert C. & Nanette T. Packard Professor of Law at University of Southern California Gould School of Law

Overview
RelSci Relationships

200

Number of Boards

5

Birthday

1943

Age

77

Relationships
RelSci Relationships are individuals Scott H. Bice likely has professional access to. A relationship does not necessarily indicate a personal connection.

Director, President & Chief Executive Officer at Arena Pharmaceuticals, Inc.

Relationship likelihood: Strong

Former Chief Executive Officer & Director at Arena Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Arena Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Arena Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Arena Pharmaceuticals, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer, Director at Sophiris Bio, Inc.

Relationship likelihood: Strong

Former Chief Financial Officer at Biogen, Inc.

Relationship likelihood: Strong

Former Chairman & Chief Executive Officer at Banta Corp.

Relationship likelihood: Strong

Managing Director at MEI Pharma, Inc.

Relationship likelihood: Strong

Co-President & Chief Executive Officer at GenomeDx Biosciences, Inc.

Relationship likelihood: Strong

Paths to Scott H. Bice
Potential Connections via
Relationship Science
You
Scott H. Bice
Robert C. & Nanette T. Packard Professor of Law at University of Southern California Gould School of Law
Career History
Robert C. & Nanette T. Packard Professor of Law
1980 - Current

The University of Southern California Law School (Gould School of Law), located in Los Angeles, California, is a law school within the University of Southern California. The oldest law school in the Southwestern United States, USC Law had its beginnings in 1896, and was officially established as a school of the university in 1904

Director
Prior

Corporate Overview Our Focus We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. In June 2012, the US Food and Drug Administration (FDA) approved our internally discovered drug, BELVIQ® (lorcaserin HCl). Click here for additional information. We are also seeking regulatory approval for BELVIQ in additional territories. Regulatory agencies outside of the US will independently review BELVIQ. In addition to BELVIQ, our internally discovered, oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; GPR119 agonists, intended for the treatment of type 2 diabetes; and nelotanserin, an inverse agonist of the serotonin 2A receptor, which we previously studied for the treatment of insomnia

Boards & Committees
Member, Board of Directors
2003 - 2018

Corporate Overview Our Focus We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. In June 2012, the US Food and Drug Administration (FDA) approved our internally discovered drug, BELVIQ® (lorcaserin HCl). Click here for additional information. We are also seeking regulatory approval for BELVIQ in additional territories. Regulatory agencies outside of the US will independently review BELVIQ. In addition to BELVIQ, our internally discovered, oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; GPR119 agonists, intended for the treatment of type 2 diabetes; and nelotanserin, an inverse agonist of the serotonin 2A receptor, which we previously studied for the treatment of insomnia

Director
1996 - 2003

WMI Mutual Insurance Co. is a private company headquartered in Salt Lake City, UT, also operating in the United States, specializing in fire, marine, and casualty insurance.

Director
1996 - 2003

Residence Mutual Insurance Co. engages in involved in fire, marine, and casualty insurance. It provides earthquake, flood, landlord, condominium and homeowners. The company was founded in 1949 and is headquartered in Irvine, CA.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$100K +
2010

Sigma Phi Epsilon Educational Foundation is a non profit organization that develops the academic, leadership, citizenship, and personal potential of SigEp’s undergraduate members. It provides support for scholarships, leadership programming, and competitive undergraduate housing. The company was founded by William L. Phillips in 1943 and is headquartered in Richmond, VA.

$100K +
2008

Sigma Phi Epsilon Educational Foundation is a non profit organization that develops the academic, leadership, citizenship, and personal potential of SigEp’s undergraduate members. It provides support for scholarships, leadership programming, and competitive undergraduate housing. The company was founded by William L. Phillips in 1943 and is headquartered in Richmond, VA.

Political Donations
$250
2012

Senator at Office of the Senator from Utah, Mitt Romney

$500
2010

Founder at One Woman Initiative

$250
2007

Senator at Office of the Senator from Utah, Mitt Romney

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Scott H. Bice. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Scott H. Bice's profile does not indicate a business or promotional relationship of any kind between RelSci and Scott H. Bice.